keyword
https://read.qxmd.com/read/38631353/expanding-strategies-to-resolve-psoriasis-like-inflammation-non-canonical-nf-%C3%AE%C2%BAb-signaling-controls-il-23-production-in-dendritic-cells
#1
JOURNAL ARTICLE
Teresa Neuwirth, Georg Stary
No abstract text is available yet for this article.
April 16, 2024: Molecular Therapy
https://read.qxmd.com/read/38630365/drug-survival-of-il-17-and-il-23-inhibitors-for-psoriasis-a-systematic-review-and-meta-analysis
#2
Sarah E Thomas, Liana Barenbrug, Gerjon Hannink, Marieke M B Seyger, Elke M G J de Jong, Juul M P A van den Reek
BACKGROUND AND OBJECTIVE: The most recently approved biologics for moderate-to-severe psoriasis are the interleukin (IL)-17 and IL-23 inhibitors. Drug survival is a frequently used outcome to assess drug performance in practice. An overview of the available drug survival studies regarding IL-17 and IL-23 inhibitors is lacking. Therefore, our objective was to assess the drug survival of IL-17 and IL-23 inhibitors for psoriasis. METHODS: A search of PubMed, Embase, Cochrane Library and Web of Science was conducted (last search 27 December, 2023)...
April 17, 2024: Drugs
https://read.qxmd.com/read/38629330/positioning-risankizumab-in-the-treatment-algorithm-of-moderate-to-severe-crohn-s-disease
#3
REVIEW
Francesca Lusetti, Ferdinando D'Amico, Mariangela Allocca, Federica Furfaro, Alessandra Zilli, Gionata Fiorino, Tommaso Lorenzo Parigi, Simona Radice, Laurent Peyrin-Biroulet, Silvio Danese
Risankizumab is a humanized monoclonal antibody that inhibits the p19 subunit of IL-23 cytokine. Recently it has been approved for the treatment of patients with moderate-to-severe Crohn's disease (CD). We conducted a scoping review to summarize the available data on risankizumab and to define its positioning in the treatment algorithm of CD. Pubmed, Embase and Scopus databases were searched up to Oct 31, 2023 to identify studies reporting efficacy and safety data of risankizumab in patients with CD. Risankizumab is an effective and safe drug for the management of patients with moderate-to-severe CD...
April 17, 2024: Immunotherapy
https://read.qxmd.com/read/38621466/comparing-chinese-herbal-medicine-bath-therapy-with-topical-calcipotriol-for-psoriasis-vulgaris-a-systematic-review-with-meta-analysis-and-association-rule-analysis
#4
REVIEW
Junyue Wang, Claire Shuiqing Zhang, Anthony Lin Zhang, Charlie Changli Xue, Chuanjian Lu
ETHNOPHARMACOLOGICAL RELEVANCE: Psoriasis is a chronic inflammatory skin disease. Vitamin D analogues are the first-line topical agents for the long-term management of psoriasis. Chinese herbal medicine (CHM) bath therapy is commonly employed for psoriasis. However, the effects and safety of CHM bath therapy compared with topical calcipotriol for psoriasis vulgaris remain inconclusive. Furthermore, the combination of herbs, a distinctive feature of CHM, is essential for its therapeutic effects due to the individual and synergistic properties of the herbs involved...
April 13, 2024: Journal of Ethnopharmacology
https://read.qxmd.com/read/38617532/cysltr1-antagonist-inhibits-th17-cell-differentiation-by-regulating-the-nf-%C3%AE%C2%BAb-signaling-for-the-treatment-of-psoriasis
#5
JOURNAL ARTICLE
Junpeng Zhao, Yi Chen, Liming Li, Huiqi Yin, Shasha Song, Yongfang Wang, Xiwei Feng, Xinyu Fan, Changxing Gao, Lingyu Gao, Yijing Zhan, Ming Zhao, Xinyu Li, Qianjin Lu
Cysteinyl leukotriene receptor 1 (CYSLTR1) is observed to increase in psoriatic skin lesions. Montelukast, a CYSLTR1 antagonist, effectively treats inflammatory disorders, such as rheumatoid arthritis, multiple sclerosis, and atopic dermatitis. Thus, blocking CYSLTR1 may be a promising strategy for psoriasis immunotherapy. We prepared a montelukast sodium cream and solution and investigated their effects on psoriasis-like skin lesions induced by imiquimod (IMQ). After the treatment, serum, skin, and spleen samples were collected for evaluation...
2024: International Journal of Biological Sciences
https://read.qxmd.com/read/38616886/the-role-of-interleukin-23-17-axis-in-psoriasis-management-a-comprehensive-review-of-clinical-trials
#6
REVIEW
Luca Potestio, Fabrizio Martora, Giuseppe Lauletta, Ylenia Vallone, Teresa Battista, Matteo Megna
Psoriasis pathogenesis is influenced by genetic factors and characterized by a complex interplay between genetic predisposition and various environmental triggers. These triggers set off metabolic processes involving inflammation, cell signaling, immune response dysregulation, and antigen presentation. Several types of innate and adaptive immune cells are involved in psoriasis. Among the cytokine cascade which leads to psoriasis development, the interleukin (IL)-23/Th17 axis, especially IL-17 production, emerges as crucial...
2024: Clinical, Cosmetic and Investigational Dermatology
https://read.qxmd.com/read/38608446/decreased-hmgcs1-inhibits-proliferation-and-inflammatory-response-of-keratinocytes-and-ameliorates-imiquimod-induced-psoriasis-via-the-stat3-il-23-axis
#7
JOURNAL ARTICLE
Lin Chen, Danqi Huang, Zhongzhou Huang, Xiuting Liu, Mingjie He, Minqing Luo, Zengqi Tang, Guozhen Tan, Qing Guo, Hui Xiong
Psoriasis is an immuno-inflammatory disease characterized by excessive keratinocyte proliferation, requiring extensive lipids. 3-hydroxy-3-methylglutaryl-coenzyme A synthase 1 (HMGCS1) is an essential enzyme in the mevalonate pathway, involved in cholesterol synthesis and the inflammatory response. However, the role of HMGCS1 in psoriasis has remained elusive. This study aims to elucidate the mechanism by which HMGCS1 controls psoriasiform inflammation. We discovered an increased abundance of HMGCS1 in psoriatic lesions when analyzing two Gene Expression Omnibus (GEO) datasets and confirmed this in psoriatic animal models and psoriatic patients by immunohistochemistry...
April 11, 2024: International Immunopharmacology
https://read.qxmd.com/read/38605952/interleukin-inhibitors-and-the-associated-risk-of-candidiasis
#8
REVIEW
Sabir Khan, Hazrat Bilal, Muhammad Nadeem Khan, Wenjie Fang, Wenqiang Chang, Bin Yin, Ning-Jing Song, Zhongrong Liu, Dongxing Zhang, Fen Yao, Xun Wang, Qian Wang, Lin Cai, Bing Hou, Jiayue Wang, Chunyan Mao, Lingxi Liu, Yuebin Zeng
Interleukins (ILs) are vital in regulating the immune system, enabling to combat fungal diseases like candidiasis effectively. Their inhibition may cause enhanced susceptibility to infection. IL inhibitors have been employed to control autoimmune diseases and inhibitors of IL-17 and IL-23, for example, have been associated with an elevated risk of Candida infection. Thus, applying IL inhibitors might impact an individual's susceptibility to Candida infections. Variations in the severity of Candida infections have been observed between individuals with different IL inhibitors, necessitating careful consideration of their specific risk profiles...
2024: Frontiers in Immunology
https://read.qxmd.com/read/38605394/determination-of-il-23-receptor-expression-and-gene-polymorphism-rs1884444-in-iranian-patients-with-ankylosing-spondylitis
#9
JOURNAL ARTICLE
Atiyeh Mellati, Samaneh Soltani, Tohid Kazemi, Nooshin Ahmadzadeh, Maryam Akhtari, Elham Madreseh, Ahmadreza Jamshidi, Elham Farhadi, Mahdi Mahmoudi
BACKGROUND: Through investigating genetic variations, it has been demonstrated that single nucleotide polymorphisms (SNPs) in the IL-23 receptor (IL23R) gene have a critical role in the pathophysiology of ankylosing spondylitis (AS). Here, we investigated whether the IL23R variant (rs1884444) is associated with AS in the Iranian population. METHODS AND MATERIAL: In this research, we analyzed rs1884444 in a group of 425 patients with AS and 400 matched controls. For DNA extraction, the phenol/chloroform technique was utilized...
April 11, 2024: BMC rheumatology
https://read.qxmd.com/read/38602626/3-3-diindolylmethane-inhibits-th17-cell-differentiation-via-impairing-irf-7-mediated-plasmacytoid-dendritic-cell-activation-in-imiquimod-induced-psoriasis-mice
#10
JOURNAL ARTICLE
Mahaboobkhan Rasool, Manupati Srikanth, Arulkumaran Rithvik
Psoriasis is a paradigmatic condition characterised by a heightened autoimmune response and chronic inflammation. However, the exact nature and the pathological causes behind it are still unknown. Growing evidence suggest dysregulated cytokine network as a result of over-activated T cells and plasmacytoid dendritic cells (pDCs) as the critical drivers in the development of psoriasis. In the present study, we aimed to investigate the therapeutic efficacy of 3,3'-diindolylmethane (DIM) on pDC activation and Th17 cell development in imiquimod (IMQ)-induced psoriasis mice...
April 11, 2024: In Vitro Cellular & Developmental Biology. Animal
https://read.qxmd.com/read/38599173/gums-make-il-23-no-professionals-needed
#11
JOURNAL ARTICLE
Mandy J McGeachy
IL-23 activates pathogenic Th17 cells to drive inflammatory disease at barrier surfaces. Kim et al. now identify oral epithelial cells as the critical producers of IL-23 in human and mouse periodontitis, linking microbial dysbiosis to non-hematopoietic regulation of IL-17-associated inflammation.
April 9, 2024: Immunity
https://read.qxmd.com/read/38598229/guselkumab-for-pityriasis-rubra-pilaris-and-dysregulation-of-il-23-il-17-and-nfkb-signaling-a-nonrandomized-trial
#12
JOURNAL ARTICLE
Rose C Velasco, Connie Shao, Brett Cutler, Jennifer Strunck, Gail Kent, Pamela B Cassidy, Keith Choate, Teri M Greiling
IMPORTANCE: There is no US Food and Drug Administration-approved treatment for pityriasis rubra pilaris (PRP), and it is common for patients to fail to experience improvement with several systemic options. Involvement of interleukin (IL) 23 suggests a potential therapeutic target. OBJECTIVE: To determine whether guselkumab, an IL-23p19 inhibitor, provides clinical improvement for participants with PRP and better understand gene and protein dysregulation in PRP. DESIGN, SETTING, AND PARTICIPANTS: This single-arm, investigator-initiated nonrandomized trial was conducted from October 2019 to August 2022 at a single-center academic university with participants from 8 states in the US...
April 10, 2024: JAMA Dermatology
https://read.qxmd.com/read/38597360/feruloylated-oligosaccharides-prevented-influenza-induced-lung-inflammation-via-the-rig-i-mavs-traf3-pathway
#13
JOURNAL ARTICLE
Li Deng, Shu-Lei Wei, Lu Wang, Jun-Qing Huang
Uncontrolled inflammation contributes significantly to the mortality in acute respiratory infections. Our previous research has demonstrated that maize bran feruloylated oligosaccharides (FOs) possess notable anti-inflammatory properties linked to the NF-kB pathway regulation. In this study, we clarified that the oral administration of FOs moderately inhibited H1N1 virus infection and reduced lung inflammation in influenza-infected mice by decreasing a wide spectrum of cytokines (IFN-α, IFN-β, IL-6, IL-10, and IL-23) in the lungs...
April 10, 2024: Journal of Agricultural and Food Chemistry
https://read.qxmd.com/read/38595016/comparative-efficacy-and-therapeutic-positioning-of-biologics-in-hidradenitis-suppurativa-a-systematic-review-with-network-meta-analysis-of-randomised-trials
#14
REVIEW
Husein Husein-ElAhmed, Sara Husein-ElAhmed
Background Hidradenitis suppurativa (HS) is a challenging inflammatory skin condition. Recently, many different biologics have been tested for HS, but the paucity of head-to-head comparative trials makes it difficult to determine the real value of each biological intervention. We aimed to determine the relative efficacy among biologics in treating moderate-to-severe HS throughout a network meta-analysis (NMA) and, to identify which pathogenetic pathways may be the most appropriate to target. Methods We comprehensively identified studies in 3 databases and clinicaltrials...
February 28, 2024: Indian Journal of Dermatology, Venereology and Leprology
https://read.qxmd.com/read/38593442/unconventional-activation-of-ire1-enhances-th17-responses-and-promotes-airway-neutrophilia
#15
JOURNAL ARTICLE
Dandan Wu, Xing Zhang, Kourtney M Zimmerly, Ruoning Wang, Amanda Livingston, Takao Iwawaki, Ashok Kumar, Xiang Wu, Matthew Campen, Michael A Mandell, Meilian Liu, Xuexian O Yang
Heightened unfolded protein responses (UPRs) are associated with the risk for asthma, including severe asthma. Treatment-refractory severe asthma manifests a neutrophilic phenotype with TH17 responses. However, how UPRs participate in the deregulation of TH17 cells leading to neutrophilic asthma remains elusive. This study found that the UPR sensor IRE1 is induced in the murine lung with fungal asthma and is highly expressed in TH17 cells relative to naïve CD4+ T cells. Cytokine (e.g. IL-23) signals induce the IRE1-XBP1s axis in a JAK2-dependent manner...
April 9, 2024: American Journal of Respiratory Cell and Molecular Biology
https://read.qxmd.com/read/38593153/interleukin-23-levels-in-umbilical-cord-blood-are-associated-with-neurodevelopmental-trajectories-in-infancy
#16
JOURNAL ARTICLE
Machiko K Asaka, Tomoko Nishimura, Hitoshi Kuwabara, Hiroaki Itoh, Nagahide Takahashi, Kenji J Tsuchiya
Our previous study, which aimed to understand the early neurodevelopmental trajectories of children with and without neurodevelopmental disorders, identified five classes of early neurodevelopmental trajectories, categorized as high normal, normal, low normal, delayed, and markedly delayed. This investigation involved measurement using the Mullen Scale of Early Learning in a representative sample of Japanese infants followed up from the age of 0 to 2 years (Nishimura et al., 2016). In the present study, we investigated the potential association between cytokine concentrations in umbilical cord serum with any of the five classes of neurodevelopmental trajectories previously assigned, as follows: high normal (N = 85, 13...
2024: PloS One
https://read.qxmd.com/read/38593108/expanding-the-psoriasis-framework-immunopathogenesis-and-treatment-updates
#17
REVIEW
Yvonne Nong, George Han, Jason E Hawkes
Psoriasis is a chronic heterogeneous condition with multiple available treatment options that have resulted in dramatic disease improvements for patients. IL-23/IL-17 signaling is the central immune signaling pathway driving psoriasis, though recent research has uncovered other key contributing signals such as IL-17C, IL-17F, IL-36, and tyrosine kinase 2 (TYK2). Novel therapeutic targets inhibiting these cytokines have expanded our understanding of the pathogenesis of psoriasis. IL-23/IL-17 signaling is critical for the development of epidermal hyperplasia and the mature psoriatic plaque in susceptible individuals...
February 2024: Cutis; Cutaneous Medicine for the Practitioner
https://read.qxmd.com/read/38584311/effectiveness-of-risankizumab-for-the-treatment-of-psoriatic-arthritis-a-multicenter-real-world-study
#18
JOURNAL ARTICLE
Dario Graceffa, Arianna Zangrilli, Giacomo Caldarola, Viviana Lora, Diego Orsini, Gala Moretta, Gianluca Pagnanelli, Alessia Provini, Cinzia Masini, Mauro Bavetta, Domenico Giordano, Antonio Richetta, Ersilla Tolino, Luca Bianchi, Ketty Peris, Francesca Sperati, Claudio Bonifati
BACKGROUND: IL-23 inhibitors were recently approved for the treatment of skin psoriasis and psoriatic arthritis (PsA). Risankizumab, a humanized monoclonal antibody that specifically binds the p19 subunit of IL-23, has proven effective on PsA in two randomized controlled trials. To date, only a few real-world data are available on this topic. METHODS: Our study aimed to prospectively evaluate the effectiveness of risankizumab in patients with PsA in a real-world setting...
April 7, 2024: International Journal of Dermatology
https://read.qxmd.com/read/38583441/assessment-of-interleukin-17a-and-23-in-the-course-of-bladder-cancer-and-selected-benign-urological-diseases
#19
JOURNAL ARTICLE
B Szymanska, J Debowski, B Malkiewicz, A Piwowar
Several cytokines have been indicated to be significantly involved in urological diseases. Interleukin 17A (IL-17A) and interleukin 23 (IL-23) have recently received attention for their involvement in inflammatory diseases and cancers. The aim of the study was to show changes in the level of pro-inflammatory interleukins IL-17A and IL-23 in patients with bladder cancer (BC) and selected urological diseases. An important cognitive aspect was to study the interdependencies between the studied interleukins and to assess their diagnostic value for such diseases...
February 2024: Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society
https://read.qxmd.com/read/38581245/dimethyl-itaconate-inhibits-antigen-specific-th17-cell-responses-and-autoimmune-inflammation-via-modulating-nrf2-stat3-signaling
#20
JOURNAL ARTICLE
Ying Wang, Chao Yang, Yubiao Hou, Jiali Wang, Kailang Zhang, Lihua Wang, Deming Sun, Xiaorong Li, Ruihua Wei, Hong Nian
Pathogenic Th17 cells play a crucial role in autoimmune diseases like uveitis and its animal model, experimental autoimmune uveitis (EAU). Dimethyl itaconate (DMI) possesses potent anti-inflammatory effects. However, there is still a lack of knowledge about the role of DMI in regulating pathogenic Th17 cells and EAU. Here, we reported that intraperitoneal administration of DMI significantly inhibited the severity of EAU via selectively suppressing Th17 cell responses. In vitro antigen stimulation studies revealed that DMI dramatically decreased the frequencies and function of antigen-specific Th17, but not Th1, cells...
April 15, 2024: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
keyword
keyword
34865
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.